RT Journal Article
SR Electronic
T1 Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1475
OP 1479
DO 10.3899/jrheum.151006
VO 43
IS 8
A1 Yosuke Hattori
A1 Toshihisa Kojima
A1 Atsushi Kaneko
A1 Daihei Kida
A1 Yuji Hirano
A1 Takayoshi Fujibayashi
A1 Kenya Terabe
A1 Yuichiro Yabe
A1 Hiroyuki Miyake
A1 Takefumi Kato
A1 Hideki Takagi
A1 Masatoshi Hayashi
A1 Takayasu Ito
A1 Yasuhide Kanayama
A1 Takeshi Oguchi
A1 Nobunori Takahashi
A1 Hisato Ishikawa
A1 Koji Funahashi
A1 Naoki Ishiguro
YR 2016
UL http://www.jrheum.org/content/43/8/1475.abstract
AB Objective. To evaluate the rates of retention and discontinuation of adalimumab (ADA) due to efficacy and safety in Japanese patients with rheumatoid arthritis (RA).Methods. All patients with RA (n = 476) who were treated with ADA in the Tsurumai Biologics Communication Registry were enrolled.Results. The retention rate of ADA was 46% at 5 years. When focusing on insufficient efficacy, previous biologics use and high baseline disease activity were significant risk factors for up to 1 year. Methotrexate (MTX) use was a significantly low risk factor after 1 year of treatment.Conclusion. Concomitant MTX contributes to the longterm efficacy of ADA therapy.